Sana Biotechnology, Inc.
About Sana Biotechnology, Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$244.2M
- Total assets
- $416.9M
- Market cap
- $745.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $250.3M
- Operating income
- -$250.3M
- Income tax
- $0
- Net income
- -$244.2M
- EPS (basic)
- $-0.96
- EPS (diluted)
- $-0.96
Balance sheet
- Total assets
- $416.9M
- Current assets
- $148.7M
- Total liabilities
- $256.0M
- Current liabilities
- $78.7M
- Shareholders’ equity
- $160.9M
Cash flow
- Operating cash flow
- -$143.8M
- Investing cash flow
- -$40.2M
- Financing cash flow
- $128.7M
- Net cash flow
- -$55.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $745.8M
- EPS (diluted)
- $-0.96
- Shares outstanding
- 277.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 4, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $244.2M.
- Trading 55% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Sana Biotechnology, Inc..
Write a review
News about Sana Biotechnology, Inc.
News & sentiment via Polygon.io
